Jupiter Neurosciences FY26 Q2 net loss widens 0.95% to $2.27 million; revenue totals $24,245
JUNS•Q2 results
Jupiter Neurosciences posted a Q2 net loss of $2.27 million, widening slightly from a year earlier; loss per share improved to $4.08.
Revenue totaled $24,245, up from no revenue a year earlier; operating loss widened to $2.74 million.
Expense and income details
R&D expense fell 21% to $600,353, while G&A climbed 44% to $2.16 million due to higher payroll and consulting costs.
Other income rose to $468,548 on a $549,098 gain from marking convertible notes to market; interest expense jumped to $90,618.
Pipeline and commercial updates
The pharmaceutical pipeline advanced with an FDA-cleared Parkinson’s Phase IIa trial starting in Q2; Nugevia supplement sales began shipping in Q4 2025.
